INTRODUCTION
The vesicular monoamine transporter (VMAT), a member of the vesicular neurotransmitter transporter family, is responsible for the translocation of monoamines (serotonin, dopamine, norepinephrine, and histamine) from the cytoplasm into synaptic vesicles via a proton electrochemical gradient generated by the vacuolar type H + -adenosine triphosphatase. 1 Two pharmacologically distinct VMAT isoforms, VMAT1 and VMAT2, have been cloned and described. [2] [3] [4] Adult human and rodent monoaminergic neurons of the central nervous system (CNS) and sympathetic postganglionic neurons express only VMAT2, [5] [6] [7] while VMAT1 is predominantly expressed in neuroendocrine cells such as chromaffi n cells of the adrenal medulla and enterochromaffi n cells of the intestinal tract. [5] [6] [7] VMAT2 is also expressed in at least 2 endocrine cell populations and in neurons. 6 Both VMAT1 and VMAT2 are more widely expressed during embryonic development. 8 Substrate recognition and inhibitor sensitivities for differences between VMAT1 and VMAT2 have been studied using membrane vesicles prepared from stable transformed cell lines from Chinese hamster ovaries (CHO) that express the respective proteins. 9 VMAT2 has a consistently higher affi nity for all of the monoamine substrates tested, particularly histamine, and has a greater sensitivity than VMAT1 to the inhibitor tetrabenazine (TBZ).
The natural alkaloid reserpine and TBZ are considered 2 classical VMAT inhibitors. 10 Reserpine inhibits the transport of amines into chromaffi n granules and synaptic storage vesicles 11 , 12 by binding with high affi nity to VMAT, presumably at the amine recognition site. It has been suggested that TBZ, on the other hand, binds to a site on VMAT that is different from the substrate binding site at which reserpine interacts. [12] [13] [14] 
VMAT2 AND NEUROPROTECTION
Oxidative deamination of monoamines by monoamine oxidase is accompanied by the reduction of molecular oxygen to a toxic product, hydrogen peroxide. 15 Therefore, maintenance of low cytoplasmic concentrations of neurotransmitters by their reuptake into synaptic vesicles for storage is important to minimize their inherent toxicity. 16 Furthermore, storage of neurotransmitters in synaptic vesicles precludes their metabolism in the cytoplasmic compartment and reduces the synthetic demands on the cell. 16 In the central nervous system, VMAT2 is the only transporter that moves cytoplasmic dopamine (DA) into synaptic vesicles for storage and subsequent exocytotic release. 1 Parkinson ' s disease is a degenerative, progressive disorder that dramatically affects neurons of the substantia nigra and the basal ganglia. The etiology of Parkinson ' s disease has not been elucidated, but exposure to endogenous or environmental toxins may contribute to the development of the disease. [17] [18] [19] [20] [21] In this regard, DA may play a role as an endogenous toxin, since the normal metabolism of DA produces hydrogen peroxide as a byproduct, and the formation of DA-associated reactive oxygen species may contribute to the loss of nigrostriatal DA neurons. 22 Accordingly, pharmacologically enhancing DA sequestration by VMAT2, and thus preventing the oxidation of DA in the cytoplasm, may be a strategy for treatment of Parkinson ' s disease.
Exposure to the neurotoxin N -methyl-4-phenyltetrahydropyridine (MPTP) results in clinical symptoms closely approximating Parkinson ' s disease. 17 N -Methyl-4-phenylpyridinium (MPP + ), the active toxic metabolite of MPTP, is a substrate for VMAT2. [23] [24] [25] [26] [27] VMAT2 sequesters MPP + in synaptic vesicles and thereby protects catecholamine-containing neurons from MPP + -induced toxicity and degeneration. 3 , 28-32 CHO cells, which are normally sensitive to MPP + toxicity, because they lack a plasma membrane amine transporter, can be made relatively insensitive to MPP + toxicity by transfection with VMAT complementary DNA. 3 In addition, when the transfected CHO cells are treated with reserpine, which inhibits VMAT2 function, the cells then become sensitive to MPP + toxicity. 3 Other studies using heterozygous VMAT2 knockout mice show that the knockouts are more susceptible to the neurotoxic effects of MPTP compared with the wild-type mice. 28 , 30 , 33 Furthermore, heterozygous VMAT2 knockout mice are more sensitive to methamphetamine-induced neurotoxicity and are more vulnerable to the toxic effects of L-3,4-dihydroxyphenylalanine (L-DOPA, a DA precursor used to treat Parkinson ' s disease) compared with wild-type mice. 34 , 35 The latter results suggest that reduction in VMAT2 activity might attenuate the effi cacy of L-DOPA therapy in Parkinson ' s patients. Finally, increased sequestration of DA in synaptic vesicles by VMAT2 has been suggested to be protective in Parkinson ' s disease. 36 Recently, studies have suggested that pharmacological agents that increase VMAT2 activity are neuroprotective. For example, methylphenidate increases vesicular DA uptake in rats and prevents persistent dopaminergic defi cits induced by highdose methamphetamine administration. 37 , 38 Pramipexole, a DA D2/D3 agonist used as a therapy for Parkinson ' s disease, increases vesicular DA uptake and protects against the loss of nigrostriatal DA neurons in methamphetamine-, 3-acetylpyridine-, and ischemia-induced neurotoxicity. [39] [40] [41] Additionally, apomorphine, a DA D2/D3 agonist used in Europe as a treatment for Parkinson ' s disease and for impotence, increases vesicular DA uptake, and this mechanism has been suggested to be important for its associated neuroprotection. 42 Taken together, the results of the above studies indicate that VMAT2 expression and function are important in counteracting the neurotoxicity of MPP + and perhaps of other environmental and endogenous neurotoxins that play an etiologic role in neurodegenerative disease. 21
VMAT2 AND PSYCHOSTIMULANT ABUSE
Psychostimulant-induced behavioral activation and reinforcement are mediated, at least in part, via interaction with neurotransmitter transporters that regulate synaptic DA concentrations. [43] [44] [45] Recent studies have demonstrated that psychostimulants alter VMAT2 function. 46 , 47 Cocaine inhibits DA transporter function, induces a rapid and reversible increase in vesicular DA uptake and dihydrotetrabenazine (DTBZ) binding, and causes a shift in the ratio of cytoplasmic to vesicular DA, all of which suggests that VMAT2 may be a novel target for the development of treatments for cocaine abuse. 48 Amphetamine and its analogs, such as methamphetamine, decrease vesicular DA sequestration by inhibiting vesicular uptake and promoting release from the vesicles. 49 , 50 Amphetamine diffuses across the vesicular membrane, decreasing the pH gradient, which results in the loss of free energy needed for monoamine sequestration. [49] [50] [51] [52] Also, amphetamine that accumulates in the vesicles com petes with monoamines for protons, resulting in an increase in the diffusion of uncharged monoamines out of the vesicle. 52 High-dose methamphetamine treatment decreases vesicular DA uptake and DTBZ binding, suggesting that there is a signifi cant alteration in VMAT2 function and localization at the vesicular membrane. 53 VMAT2 heterologous knockout mice exhibit reduced amphetamine-conditioned place preference (reward) and enhanced sensitivity to the locomotor effects of apomorphine, ethanol, cocaine, and amphetamine. 28 , 54 VMAT2 knockout studies also indicate that VMAT2 plays an important role in mediating the behavioral effects of psychostimulants. Taken together, these results support the idea that VMAT2 should be considered as a valid target for the development of pharmacotherapies to treat psychostimulant abuse. Other evidence supporting the role of VMAT2 in psychostimulant pharmacology is the fi nding that benzoquinolizine derivatives, such as TBZ, which have high affi nity for VMAT2, decrease locomotor activity and aggressiveness in monkeys 55 and decrease methamphetamineinduced hyperactivity in rodent animal models. 55
VMAT2 LIGANDS

TBZ and Its Analogs
TBZ ( 1 , Figure 1 ), a benzoquinolizine compound, has been shown to deplete cerebral monoamines in rat brain by reversibly inhibiting VMAT2. 56 First introduced in 1956 as an antipsychotic drug, 57 TBZ is currently used to treat hyperkinetic movement disorders, such as chorea associated with Huntington ' s disease, tics in Tourette ' s syndrome, and movement stereotypes in tardive dyskinesia. [58] [59] [60] The side effects associated with TBZ include sedation, depression, akathisia, and parkinsonism. 58 TBZ inhibits catecholamine uptake by VMAT2 with a K i of 3 nM 14 and acts as an inhibitor of both presynaptic and postsynaptic DA receptors in rat brain. 61 [ 11 C]TBZ (label on the 9-O -methyl group) has been synthesized 62 and used as an in vivo radioligand for positron emission tomography (PET) imaging of VMAT2. [63] [64] [65] [66] TBZ analogs have been synthesized with different alkyl groups at the C-3 position in the molecule, such as compound Ro 4-1632 ( 2 , Figure 1 ). These analogs retain good amine-depleting activity. 55 In vivo, TBZ is rapidly and extensively metabolized to its reduced form, DTBZ ( 3 , Figure 1 ). 67 [ 3 H]DTBZ (label on the C-2 hydrogen) has been used as a selective radioligand in in vitro brain homogenate binding studies and in autoradiographic studies, and is reported to have a K d value of 3.0 nM. 13 , 14 , 68-70 [ 11 C]DTBZ (label on the 9-O -methyl group) has also been synthesized 71 and used for in vivo PET imaging of VMAT2. 66 , 72 TBZ contains 2 chiral carbon centers at C-3 and C-11b; thus, theoretically, TBZ can exist as 4 possible stereoisomers (3R,11bR; 3S,11bS; 3R,11bS; and 3S,11bR). TBZ usually refers to the racemic compound, that is, a 1:1 mixture of the 3R,11bR and 3S,11bS isomers. Synthetic DTBZ, the product of hydride reduction of the 2-keto group of TBZ, can exist in 2 a -DTBZ forms (2R,3R,11bR, 3a ; and 2S,3S,11bS, 3b , Figure 2 ) and 2 b -DTBZ forms (2S,3R,11bR, 3c ; and 2R,3S,11bS, 3d , Figure 2 ). a -DTBZ and b -DTBZ can be separated by column chromatography, and the a -DTBZ isomer ( K i = 6 nM) shows slightly higher binding affi nity in vitro for rat brain VMAT2 than does b -DTBZ ( K i = 20 nM). 73 The 2 enantiomers of a -DTBZ have been separated using chiral High Performance Liquid Chromatography (HPLC). The (+)-isomer (2R,3R,11bR, 3a ) 74 shows high affi nity in vitro ( K i = 0.97 nM) for rat VMAT2, whereas the ( -)-isomer shows very low affi nity for VMAT2 ( K i = 2.2 μM). Thus the binding of a -DTBZ to VMAT2 is enantioselective, with the (+)-isomer having higher affi nity. 75 , 76 Another 4 possible DTBZ isomers (2S,3S,11bR, 3e ; 2R,3R,11bS, 3f ; 2R,3S,11bR, 3g ; 2S,3R,11bS, 3h , Figure 3 ) have been synthesized and tested for inhibition of VMAT2 binding using rat vesicular membranes. Isomer 3g showed the highest affi nity ( K i = 28 nM) in the [ 3 H]DTBZ binding assay. 77 , 78 Methoxytetrabenazine (MTBZ) ( 4 , Figure 1 ) is another TBZ analog with high affi nity ( K d = 3.9 nM) for VMAT2. 79 Similar to DTBZ, [ 3 H] and [ 11 C]MTBZ have also been synthesized 73 and used in in vitro and in vivo studies. [79] [80] [81] Nucleophilic addition of organometallic reagents to the C-2 keto group of TBZ generated a series of 2-alkylated DTBZ analogs, such as the 2-Me, 2-Et, 2-Pr, 2-iso-Pr, and 2-iso-Bu derivatives (all racemic mixtures, Figure 4 ). [82] [83] [84] [85] These compounds have been evaluated for inhibition of [ 3 H]MTBZ binding to VMAT2 in rat striatum. 85 The b -methyl compound 5a showed the highest affi nity ( K i = 2.6 nM) in this series, with a nearly 5-fold higher affi nity than its diastereomer 5b ( K i = 12 nM), which is consistent with the fi nding that a -DTBZ exhibits higher affi nity for VMAT2 than does b -DTBZ. 73 Compound 5b and compounds 6 to 9 all contain a b -hydroxyl group and showed a general decrease in binding affi nity upon either lengthening or branching of the alkyl group at C-2. 85 These results indicate that analogs containing considerable steric bulk at position 2 can be tolerated. Thus, compound 10 ( Figure 4 ) , in which an 125 I atom has been introduced for autoradiographic studies of VMAT2, has been synthesized. 86 ( ± )-Compound 10 can be separated by chiral HPLC into its optical isomers, and the fi rst eluted enantiomer binds to VMAT2 with a K d of 0.22 nM. 87 Structure-activity relationship (SAR) studies involving TBZ analogs have shown that quaternization of the amine nitrogen at position 5, aromatization of ring C, and elimination of the carbonyl group afforded compounds that were devoid ( 3a-d ) . of monoamine-depleting activity. 55 , 88 Thus, a basic amine nitrogen at position 5 is a prerequisite for TBZ-like activity. 89 Also, methoxy groups at positions 9 and 10 appear to be essential for TBZ-like activity; the methylenedioxy compound 11 ( Figure 5 ) was 3 orders of magnitude less potent than Ro 4-1284 ( 6 ). 90 Replacing the carbonyl oxygen in TBZ with a bis -methylthio group (compound 12 , Figure 5 ) affords a compound with similar activity to TBZ. 91 Olefi nation of the carbonyl group to afford compound 13 ( Figure 5 ) 
Ketanserin and Its Analogs
Ketanserin ( 25 , Figure 8 ), a well-known serotonin 5-HT2 receptor antagonist, 95 also binds to VMAT on chromaffi n granules and synaptic vesicles. [96] [97] [98] In the studies by Darchen et al, 96 Henry et al, 97 and Leysen et al, 98 A ketanserin derivative, 7-azidoketanserin ( 26 , Figure 8 ), also binds to the TBZ binding site of bovine chromaffi n granule membranes with a K i of 23 nM (inhibition of [ 3 H]DTBZ binding). 99 An iodinated azido derivative of ketanserin, 7-azido-8-iodoketanserin ( 27 , Figure 8 ), binds to the same specifi c TBZ binding site as ketanserin with a K d of 5.5 nM at 0ºC 99 ; 7-azido-8-[ 125 I]iodoketanserin has been successfully used for photoaffi nity labeling of TBZ binding sites of different tissues, including rat striatum, rabbit platelets, human pheochromocytoma, and human adrenal medulla. 99 Lengthening the distance between the piperidine and the benzoyleneurea moieties of the ketanserin molecule by addition of 2 methylene groups results in a compound ( 28 , Figure 9 ) that exhibits a 20-fold decrease in affi nity ( K i = 950 nM) for the [ 3 H]DTBZ binding site. 96 Reducing the keto group of ketanserin (compound 29 , Figure 9 ) also decreases affi nity ( K i = 350 nM) for this site. Additionally, replacing the benzoyleneurea moiety with other heterocycles (eg, compounds 30-32 , Figure 9 ) also decreases affi nity ( K i = 950, 814, and 3600 nM, respectively) for the [ 3 H]DTBZ binding site. However, minor structural changes to the benzoyleneurea moiety, such as introducing a hydroxyl group into the ring (compound 33 , Figure 9 ) or replacing 1 of the oxygen atoms with a sulfur atom (compound 34 , Figure  9 ), retains the affi nity ( K i = 14 and 40 nM, respectively). 96
Lobeline and Its Analogs
A lipophilic alkaloid from Lobelia infl ata , ( -)-lobeline (lobeline, 2R,6S,10S-, 35 , Figure 10 ), displaces [ 3 H]nicotine binding from native nicotinic receptors in the CNS with high affi nity ( K i = 4-30 nM). [100] [101] [102] [103] [104] Although lobeline has no structural resemblance to nicotine, and SARs do not suggest a common pharmacophore, 105 it has many nicotinelike effects, such as tachycardia and hypertension, 106 bradycardia and hypotension in anesthetized rats, 107 anxiolytic activity, 108 and improvement of learning and memory. 109 In contrast to nicotine, lobeline only marginally supports selfadministration in mice 110 and does not support self-administration in rats. 111 Additionally, chronic lobeline treatment does not increase locomotor activity in rats and does not produce conditioned place preference. 112 , 113 Thus, lobeline and nicotine have different effects in behavioral and neurochemical studies, suggesting that they do not act via a common mechanism. Nevertheless, lobeline has often been considered to be a nicotinic receptor agonist. Conversely, we and others have established that lobeline acts as a potent, but nonselective, nicotinic receptor antagonist. 104 , 114-117 Lobeline inhibits nicotine-evoked [ 3 H]DA overfl ow from rat striatal slices with an IC 50 of 1 μM, suggesting that lobeline acts as an antagonist at nicotinic receptors mediating nicotine-evoked DA release (ie, a 6 b 2 b 3* subtype). 116 Lobeline also inhibits nicotine-evoked 86 Rb + effl ux from rat thalamic synaptosomes with an IC 50 of 0.7 μM, indicating that lobeline is also an antagonist at a 4 b 2* nicotinic receptors. 116 Moreover, lobeline also inhibits [ 3 H]methyllycaconitine binding to rat brain membranes with a K i of 6.26 μM, indicating that there is an interaction with the a 7* nicotinic receptor subtype. 117 Lobeline has also been reported to be an antagonist (IC 50 of 8.5 μM) at human a 7* nicotinic receptors expressed in Xenopus oocytes. 118 In addition to interacting with nicotinic acetylcholine receptors (nAChRs), lobeline inhibits [ 3 H]DTBZ binding to VMAT2 with an IC 50 of 0.90 μM and inhibits [ 3 H]DA uptake into rat striatal vesicle preparations with an IC 50 of 0.88 μM. 119 , 120 Therefore, lobeline is a nonselective nAChR antagonist that also inhibits VMAT2 function. Importantly, lobeline has been shown to inhibit both the neurochemical and the behavioral effects of amphetamine in rodents. 111 , 121-123 The mechanism underlying the lobeline-induced inhibition of these effects has been suggested to be noncompetitive inhibition of VMAT2 function. 114 The observation that lobeline is not self-administered is consistent with fi ndings that lobeline does not evoke DA release. 111 , 114 , 119 Furthermore, the observation that lobeline inhibits methamphetamine-evoked DA release from superfused rat striatal slices 116 is consistent with its ability to decrease methamphetamine selfadministration in rats. 123 These studies clearly implicate VMAT2 as a potential target for the development of agents to treat methamphetamine abuse. Regardless, lobeline is a novel prototypical molecule from which subtype-selective nAChR ligands and selective VMAT2 inhibitors may be developed following appropriate structural modifi cation.
Systematic structural modifi cation of the lobeline molecule provided 2 non-oxygen-containing lobeline analogs: Figure 11 ) and N -methyl-2,6-di-( cisphenylethyl)piperidine (lobelane, 37a , Figure 11 ). The latter 2 analogs showed affi nity for VMAT2 at the TBZ binding site ( K i of 9.88 μM for 36a , and 0.97 μM for 37a ), with negligible affi nity for the ligand binding sites on a 4 b 2* and a 7* nAChRs. 117 , 124 Compounds 36b and 36c ( Figure 11 ) are 2 stereoisomers of 36a ; 36c was equipotent with its meso -isomer, MTD, but 36b was slightly less potent (2-to 3-fold) than MTD at VMAT2. Within the lobelane series of compounds (ie, compounds 37a , 37b , and 37c , Figure 11 ), a change in C2, C6 stereochemistry from cis to trans afforded a modest reduction (5-to 6-fold) in affi nity at VMAT2. The trans enantiomers 37b and 37c exhibited comparable affi nities at VMAT2. These data indicate that the VMAT2 binding site is not sensitive to major stereochemical changes to the MTD and lobelane molecules at the C2 and C6 piperidino ring carbons.
Interestingly, 2 conformationally fl exible, ring-opened compounds, 38a and 38b ( Figure 12 ) ( K i = 5.21 and 3.96 μM, respectively) and 2 acyclic compounds, 39 and 40 ( Figure  12 ) ( K i = 2.37 and 3.07 μM, respectively), exhibited lower, but comparable, affi nity for VMAT2 compared with lobelane. Thus, ring opening or complete removal of the piperidine ring results in only a modest reduction in affi nity at VMAT2 compared with lobelane ( 37a ). The presence of a basic amine functionality is likely a prerequisite for VMAT2 recognition, as is evidenced by the fact that quaternized compounds 41 ( K i > 100 μM) and 42 ( K i = 16.5 μM) ( Figure 12 ) show signifi cant loss in affi nity for VMAT2. 124 The entire lobelane structure appears to be critical for highaffi nity binding at VMAT2, since fragments of lobelane or MTD, such as compounds 43 and 44 ( Figure 13 ) (both K i > 100 μM), exhibited no affi nity for VMAT2. 125 Isomerized lobelane analogs, such as compound 45 ( Figure  14 ) ( K i = 1.36 m M), retained affi nity for VMAT2, indicating that the position of the piperidine N atom relative to the C2 and C6 side chains does not appear to be critical for VMAT2 interaction, and that the VMAT2 binding site can tolerate changes in distance between the piperidine nitrogen and the 2 phenyl rings. 125 In the lobelane structure, changes in the N -substituent can also be tolerated. Nor -lobelane ( 
3-Amino-2-Phenylpropene Derivatives
Recently, a series of 3-amino-2-phenylpropene derivatives ( Figure 16 ) have been reported as novel competitive inhibitors of the bovine chromaffi n granule membrane monoamine transporter (bVMAT2). 127 With a K i of 40.3 m M, 3-amino-2-phenylpropene (APP, 56 ) inhibits DA uptake into bVMAT2. Introduction of a hydroxyl group into the 3 or 4 
VMAT2 STRUCTURE AND MOLECULAR BASIS FOR BINDING
Predictions regarding the molecular structure of VMAT2 from its protein sequence are that it comprises 12 putative transmembrane domains (TMDs) with both N-and C-termini in the cytoplasm and a large, hydrophobic, N -glycosylated loop between TMDs 1 and 2 facing the vesicle lumen. 1 Structural biology studies have identifi ed important residues that may contribute to ligand binding and monoamine transport. Mutagenesis studies indicate that aspartate 33, which contains a negative charge, in TMD1 and serines 180 to 182 in TMD3 of VMAT2 play a critical role in substrate recognition, presumably by interacting with the protonated amino group of the ligand and hydroxyl groups on the catechol or indole ring, respectively. 128 In addition, lysine 139 in TMD2 and aspartate 427 in TMD11 of VMAT2 interact to form an ion pair and appear to provide a structural framework for substrate recognition. 129 Experiments employing a chimera of VMAT1 and VMAT2 indicate that 2 domains, TMD5 through TMD8 and TMD9 through TMD12, cooperate to confer the high-affi nity interaction of VMAT2 with TBZ and histamine. 130 In addition, the domain encompassing TMD3 and TMD4 infl uences serotonin affi nity but not histamine affi nity or TBZ sensitivity. 130 The domain encompassing TMD5 through TMD7 of VMAT2 in the context of N-terminal VMAT2 sequences reduces the apparent affi nity for serotonin but not histamine or the sensitivity to TBZ. 130 Tyrosine 434 and aspartate 461 in TMD9 through TMD12 are identifi ed as being responsible for the high-affi nity interaction of TBZ, histamine, and serotonin, but not for DA. 131 Photoaffi nity labeling of purifi ed rat VMAT2 indicates that TMD1 and TMD10/11 are possibly juxtaposed and may interact in a functionally signifi cant manner. 132 
CONCLUSION
Signifi cant progress has been made over the last 20 years in elucidating the role of VMAT2 in monoamine transport and its potential as a therapeutic target. VMAT2 sequesters cytoplasmic DA and thus prevents the oxidation of DA in the cytoplasm; VMAT2 also sequesters neurotoxins within vesicles. These data indicate that VMAT2 may play a role in neuroprotection and that molecules that interact with VMAT2 may have value as treatments for diseases such as Parkinson ' s disease. VMAT2 may also be a novel target for the development of treatments for psychostimulant abuse, and the discovery of molecules that modulate VMAT2 function may afford useful tools for examining the pivotal role of this transporter in the neurochemical and behavioral effects of psychostimulant drugs, thus providing potential pharmacotherapies. 
